JP6062859B2 - プログラム、コンピュータで読み取り可能な媒体、薬剤送達コントローラー及び方法 - Google Patents

プログラム、コンピュータで読み取り可能な媒体、薬剤送達コントローラー及び方法 Download PDF

Info

Publication number
JP6062859B2
JP6062859B2 JP2013533983A JP2013533983A JP6062859B2 JP 6062859 B2 JP6062859 B2 JP 6062859B2 JP 2013533983 A JP2013533983 A JP 2013533983A JP 2013533983 A JP2013533983 A JP 2013533983A JP 6062859 B2 JP6062859 B2 JP 6062859B2
Authority
JP
Japan
Prior art keywords
zone
blood glucose
physiological
controller
mpc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2013533983A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013542011A (ja
JP2013542011A5 (https=
Inventor
ドイル，フランシス・ジエイ，ザ・サード
グロスマン，ベンヤミン
ダツソー，エーヤル
ジヨバノビツチ，ロイス
ジサー，ハワード
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California, University of California San Diego UCSD filed Critical University of California
Publication of JP2013542011A publication Critical patent/JP2013542011A/ja
Publication of JP2013542011A5 publication Critical patent/JP2013542011A5/ja
Application granted granted Critical
Publication of JP6062859B2 publication Critical patent/JP6062859B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • G16H20/17—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • A61M31/002—Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/66—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood sugars, e.g. galactose
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/50—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16Z—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS, NOT OTHERWISE PROVIDED FOR
    • G16Z99/00—Subject matter not provided for in other main groups of this subclass
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/62—Insulins

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pathology (AREA)
  • Medical Informatics (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Primary Health Care (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Databases & Information Systems (AREA)
  • Data Mining & Analysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
JP2013533983A 2010-10-12 2011-10-12 プログラム、コンピュータで読み取り可能な媒体、薬剤送達コントローラー及び方法 Active JP6062859B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39239910P 2010-10-12 2010-10-12
US61/392,399 2010-10-12
PCT/US2011/056022 WO2012051344A2 (en) 2010-10-12 2011-10-12 Maintaining multiple defined physiological zones using model predictive control

Publications (3)

Publication Number Publication Date
JP2013542011A JP2013542011A (ja) 2013-11-21
JP2013542011A5 JP2013542011A5 (https=) 2014-11-27
JP6062859B2 true JP6062859B2 (ja) 2017-01-18

Family

ID=45938960

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013533983A Active JP6062859B2 (ja) 2010-10-12 2011-10-12 プログラム、コンピュータで読み取り可能な媒体、薬剤送達コントローラー及び方法

Country Status (7)

Country Link
US (1) US9700708B2 (https=)
EP (1) EP2628115B1 (https=)
JP (1) JP6062859B2 (https=)
CA (1) CA2816388C (https=)
DK (1) DK2628115T3 (https=)
ES (1) ES2544874T3 (https=)
WO (1) WO2012051344A2 (https=)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8417311B2 (en) 2008-09-12 2013-04-09 Optiscan Biomedical Corporation Fluid component analysis system and method for glucose monitoring and control
WO2009049252A1 (en) 2007-10-10 2009-04-16 Optiscan Biomedical Corporation Fluid component analysis system and method for glucose monitoring and control
US7959598B2 (en) 2008-08-20 2011-06-14 Asante Solutions, Inc. Infusion pump systems and methods
US9757510B2 (en) 2012-06-29 2017-09-12 Animas Corporation Method and system to handle manual boluses or meal events for closed-loop controllers
US9486578B2 (en) * 2012-12-07 2016-11-08 Animas Corporation Method and system for tuning a closed-loop controller for an artificial pancreas
US9907909B2 (en) * 2012-12-20 2018-03-06 Animas Corporation Method and system for a hybrid control-to-target and control-to-range model predictive control of an artificial pancreas
KR102212020B1 (ko) * 2013-01-14 2021-02-05 더 리전트 오브 더 유니버시티 오브 캘리포니아 제1형 당뇨병 응용을 위한 인공 췌장에 대한 모델 예측 제어 문제에서의 일주기 목표-구역 조절
EP2973095B1 (en) 2013-03-15 2018-05-09 Animas Corporation Insulin time-action model
US9795737B2 (en) 2013-03-15 2017-10-24 Animas Corporation Method and system for closed-loop control of an artificial pancreas
US9517306B2 (en) 2013-03-15 2016-12-13 Animas Corporation Method and system for closed-loop control of an artificial pancreas
US9561324B2 (en) 2013-07-19 2017-02-07 Bigfoot Biomedical, Inc. Infusion pump system and method
US9474855B2 (en) 2013-10-04 2016-10-25 Animas Corporation Method and system for controlling a tuning factor due to sensor replacement for closed-loop controller in an artificial pancreas
US9861747B2 (en) 2013-12-05 2018-01-09 Lifescan, Inc. Method and system for management of diabetes with a glucose monitor and infusion pump to provide feedback on bolus dosing
GB2523989B (en) 2014-01-30 2020-07-29 Insulet Netherlands B V Therapeutic product delivery system and method of pairing
AU2015301146B2 (en) 2014-08-06 2020-06-25 Regents Of The University Of California Moving-horizon state-initializer for control applications
CN111905188B (zh) 2015-02-18 2022-07-22 英赛罗公司 流体输送和输注装置及其使用方法
US10275573B2 (en) 2016-01-13 2019-04-30 Bigfoot Biomedical, Inc. User interface for diabetes management system
US10806859B2 (en) 2016-01-14 2020-10-20 Bigfoot Biomedical, Inc. Adjusting insulin delivery rates
HK1256995A1 (zh) 2016-01-14 2019-10-11 Bigfoot Biomedical, Inc. 药物输送设备、系统和方法中的阻塞解决方案
FR3047098B1 (fr) * 2016-01-21 2018-05-25 Voluntis Gestion de l'equilibre glycemique d'un patient diabetique
RU2737326C2 (ru) * 2016-02-05 2020-11-27 Энимас Корпорейшн Средство наглядного представления и анализа для системы доставки лекарственных средств
US12383166B2 (en) 2016-05-23 2025-08-12 Insulet Corporation Insulin delivery system and methods with risk-based set points
WO2018058041A1 (en) 2016-09-23 2018-03-29 Insulet Corporation Fluid delivery device with sensor
CA3037432A1 (en) 2016-12-12 2018-06-21 Bigfoot Biomedical, Inc. Alarms and alerts for medication delivery devices and related systems and methods
US10583250B2 (en) 2017-01-13 2020-03-10 Bigfoot Biomedical, Inc. System and method for adjusting insulin delivery
US10758675B2 (en) 2017-01-13 2020-09-01 Bigfoot Biomedical, Inc. System and method for adjusting insulin delivery
US10881793B2 (en) 2017-01-13 2021-01-05 Bigfoot Biomedical, Inc. System and method for adjusting insulin delivery
EP3568860B1 (en) 2017-01-13 2025-12-10 Insulet Corporation Insulin delivery methods, systems and devices
US10500334B2 (en) 2017-01-13 2019-12-10 Bigfoot Biomedical, Inc. System and method for adjusting insulin delivery
EP4708311A2 (en) 2017-01-13 2026-03-11 Insulet Corporation Insulin delivery methods, systems and devices
US11497851B2 (en) 2017-03-31 2022-11-15 Lifescan Ip Holdings, Llc Maintaining maximum dosing limits for closed loop insulin management systems
US10729849B2 (en) 2017-04-07 2020-08-04 LifeSpan IP Holdings, LLC Insulin-on-board accounting in an artificial pancreas system
US11147920B2 (en) 2017-04-18 2021-10-19 Lifescan Ip Holdings, Llc Diabetes management system with automatic basal and manual bolus insulin control
CA3198598A1 (en) 2017-05-05 2018-11-08 Eli Lilly And Company Closed loop control of physiological glucose
EP3438858A1 (en) 2017-08-02 2019-02-06 Diabeloop Closed-loop blood glucose control systems and methods
WO2019125932A1 (en) 2017-12-21 2019-06-27 Eli Lilly And Company Closed loop control of physiological glucose
JP6938363B2 (ja) * 2017-12-27 2021-09-22 オムロンヘルスケア株式会社 情報処理装置、生体情報測定装置、方法及びプログラム
USD928199S1 (en) 2018-04-02 2021-08-17 Bigfoot Biomedical, Inc. Medication delivery device with icons
US11147919B2 (en) 2018-04-23 2021-10-19 Medtronic Minimed, Inc. Methodology to recommend and implement adjustments to a fluid infusion device of a medication delivery system
US11158413B2 (en) * 2018-04-23 2021-10-26 Medtronic Minimed, Inc. Personalized closed loop medication delivery system that utilizes a digital twin of the patient
EP3788628B1 (en) 2018-05-04 2024-12-11 Insulet Corporation Safety constraints for a control algorithm-based drug delivery system
US12562251B1 (en) 2018-05-09 2026-02-24 Bigfoot Biomedical, Inc. Computing architecture for assuring the provenance of medication therapy related parameters, and related systems, methods and devices
CN112313754A (zh) 2018-06-22 2021-02-02 伊莱利利公司 胰岛素和普兰林肽输送系统、方法和设备
US11628251B2 (en) 2018-09-28 2023-04-18 Insulet Corporation Activity mode for artificial pancreas system
EP3864668A1 (en) 2018-10-11 2021-08-18 Insulet Corporation Event detection for drug delivery system
USD920343S1 (en) 2019-01-09 2021-05-25 Bigfoot Biomedical, Inc. Display screen or portion thereof with graphical user interface associated with insulin delivery
US11986629B2 (en) 2019-06-11 2024-05-21 Medtronic Minimed, Inc. Personalized closed loop optimization systems and methods
US11801344B2 (en) 2019-09-13 2023-10-31 Insulet Corporation Blood glucose rate of change modulation of meal and correction insulin bolus quantity
US11935637B2 (en) 2019-09-27 2024-03-19 Insulet Corporation Onboarding and total daily insulin adaptivity
WO2021113647A1 (en) 2019-12-06 2021-06-10 Insulet Corporation Techniques and devices providing adaptivity and personalization in diabetes treatment
US11833329B2 (en) 2019-12-20 2023-12-05 Insulet Corporation Techniques for improved automatic drug delivery performance using delivery tendencies from past delivery history and use patterns
JP7512395B2 (ja) 2020-01-06 2024-07-08 インスレット コーポレイション 持続する残差に基づく食事および／または運動行為の予測
US12370307B2 (en) 2020-02-03 2025-07-29 Insulet Corporation Use of fuzzy logic in predicting user behavior affecting blood glucose concentration in a closed loop control system of an automated insulin delivery device
US11551802B2 (en) 2020-02-11 2023-01-10 Insulet Corporation Early meal detection and calorie intake detection
US11547800B2 (en) 2020-02-12 2023-01-10 Insulet Corporation User parameter dependent cost function for personalized reduction of hypoglycemia and/or hyperglycemia in a closed loop artificial pancreas system
US11986630B2 (en) 2020-02-12 2024-05-21 Insulet Corporation Dual hormone delivery system for reducing impending hypoglycemia and/or hyperglycemia risk
US11324889B2 (en) 2020-02-14 2022-05-10 Insulet Corporation Compensation for missing readings from a glucose monitor in an automated insulin delivery system
US12495994B2 (en) 2020-02-20 2025-12-16 Insulet Corporation Meal bolus subcategories in model based insulin therapy
US11607493B2 (en) 2020-04-06 2023-03-21 Insulet Corporation Initial total daily insulin setting for user onboarding
WO2022020197A1 (en) 2020-07-22 2022-01-27 Insulet Corporation Open-loop insulin delivery basal parameters based on insulin delivery records
US11684716B2 (en) 2020-07-31 2023-06-27 Insulet Corporation Techniques to reduce risk of occlusions in drug delivery systems
US12569619B2 (en) 2020-09-21 2026-03-10 Insulet Corporation Techniques for determining automated insulin delivery dosages
EP4221588A1 (en) 2020-09-30 2023-08-09 Insulet Corporation Secure wireless communications between a glucose monitor and other devices
WO2022072332A1 (en) 2020-09-30 2022-04-07 Insulet Corporation Drug delivery device with integrated optical-based glucose monitor
US11160925B1 (en) 2021-01-29 2021-11-02 Insulet Corporation Automatic drug delivery system for delivery of a GLP-1 therapeutic
US11904140B2 (en) 2021-03-10 2024-02-20 Insulet Corporation Adaptable asymmetric medicament cost component in a control system for medicament delivery
EP4305636A1 (en) 2021-03-10 2024-01-17 Insulet Corporation A medicament delivery device with an adjustable and piecewise analyte level cost component to address persistent positive analyte level excursions
US12592306B2 (en) 2021-04-28 2026-03-31 Insulet Corporation Devices and methods for initialization of drug delivery devices using measured analyte sensor information
US12496398B2 (en) 2021-05-28 2025-12-16 Insulet Corporation Threshold based automatic glucose control response
US12406760B2 (en) 2021-06-07 2025-09-02 Insulet Corporation Exercise safety prediction based on physiological conditions
US12514980B2 (en) 2021-06-30 2026-01-06 Insulet Corporation Adjustment of medicament delivery by a medicament delivery device based on menstrual cycle phase
US12521486B2 (en) 2021-07-16 2026-01-13 Insulet Corporation Method for modification of insulin delivery during pregnancy in automatic insulin delivery systems
WO2023049900A1 (en) 2021-09-27 2023-03-30 Insulet Corporation Techniques enabling adaptation of parameters in aid systems by user input
US11439754B1 (en) 2021-12-01 2022-09-13 Insulet Corporation Optimizing embedded formulations for drug delivery
EP4243030A1 (en) 2022-03-09 2023-09-13 Insulet Corporation Adjusting medicament delivery parameters in an open loop medicament delivery mode
CN120457493A (zh) 2023-01-06 2025-08-08 英赛罗公司 自动或手动启动的随餐推注输送及随后的自动安全约束放宽
US20250166810A1 (en) * 2023-11-22 2025-05-22 Cilag Gmbh International Data streams multi-system interaction

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3251224B2 (ja) * 1998-02-26 2002-01-28 勲 長澤 病棟情報システム
US8423113B2 (en) * 2003-07-25 2013-04-16 Dexcom, Inc. Systems and methods for processing sensor data
US8369919B2 (en) * 2003-08-01 2013-02-05 Dexcom, Inc. Systems and methods for processing sensor data
US9135402B2 (en) * 2007-12-17 2015-09-15 Dexcom, Inc. Systems and methods for processing sensor data
WO2006124716A2 (en) * 2005-05-13 2006-11-23 Trustees Of Boston University Fully automated control system for type 1 diabetes
US9392969B2 (en) * 2008-08-31 2016-07-19 Abbott Diabetes Care Inc. Closed loop control and signal attenuation detection
WO2008057384A2 (en) * 2006-11-02 2008-05-15 The University Of North Carolina At Chapel Hill Methods and systems for determining an intravenous insulin infusion rate
US20080154513A1 (en) * 2006-12-21 2008-06-26 University Of Virginia Patent Foundation Systems, Methods and Computer Program Codes for Recognition of Patterns of Hyperglycemia and Hypoglycemia, Increased Glucose Variability, and Ineffective Self-Monitoring in Diabetes
EP2139540A1 (en) * 2007-03-19 2010-01-06 Medingo Ltd. User interface for selecting bolus doses in a drug delivery device
US8221345B2 (en) * 2007-05-30 2012-07-17 Smiths Medical Asd, Inc. Insulin pump based expert system
WO2009139846A1 (en) * 2008-05-12 2009-11-19 Department Of Veterans Affairs Automated system and method for diabetes control
CA2753650A1 (en) * 2008-11-26 2010-06-03 University Of Virginia Patent Foundation Method, system, and computer program product for tracking of blood glucose variability in diabetes
US8562587B2 (en) * 2009-02-25 2013-10-22 University Of Virginia Patent Foundation CGM-based prevention of hypoglycemia via hypoglycemia risk assessment and smooth reduction of insulin delivery

Also Published As

Publication number Publication date
JP2013542011A (ja) 2013-11-21
WO2012051344A2 (en) 2012-04-19
EP2628115B1 (en) 2015-06-03
HK1182496A1 (en) 2013-11-29
US20130231642A1 (en) 2013-09-05
DK2628115T3 (en) 2015-08-24
EP2628115A4 (en) 2014-04-23
ES2544874T3 (es) 2015-09-04
CA2816388A1 (en) 2012-04-19
CA2816388C (en) 2016-12-06
US9700708B2 (en) 2017-07-11
EP2628115A2 (en) 2013-08-21
WO2012051344A3 (en) 2012-07-19

Similar Documents

Publication Publication Date Title
JP6062859B2 (ja) プログラム、コンピュータで読み取り可能な媒体、薬剤送達コントローラー及び方法
EP2967450B1 (en) System for closed-loop control of an artificial pancreas
JP6378164B2 (ja) 血糖制御システム
JP7278216B2 (ja) 遡及的な仮想基礎レートを用いて、インスリン送達を制御するための方法およびシステム
EP2521483B1 (en) System to deliver insulin to a subject
Cobelli et al. Artificial pancreas: past, present, future
Patek et al. Modular closed-loop control of diabetes
RU2602040C2 (ru) Способ, система и машиночитаемый носитель для адаптационного рекомендательного контроля сахарного диабета
US9283323B2 (en) Insulin pump
Palerm et al. A run-to-run control strategy to adjust basal insulin infusion rates in type 1 diabetes
Mughal et al. A comprehensive review of models and nonlinear control strategies for blood glucose regulation in artificial pancreas
Herrero et al. A bio-inspired glucose controller based on pancreatic β-cell physiology
US20130046281A1 (en) Closed Loop Infusion Formulation Delivery System
BR112019021802A2 (pt) sistema de gerenciamento do diabetes com controle de insulina basal automático e de bolus manual
KR20120047841A (ko) 당뇨병 관련 치료의 자동 감시를 위한 방법 및 시스템
WO2015056259A1 (en) System and method for improved artificial pancreas management
TW201503921A (zh) 用於人工胰臟之混合式控制至目標及控制至範圍模型預測控制的方法及系統
WO2017123805A1 (en) Predictive control model for the artificial pancreas using past predictions
Messori et al. Artificial pancreas: from in-silico to in-vivo
Doyle et al. I. Glucose control strategies for treating type 1 diabetes mellitus
CN110352460A (zh) 人工胰腺
Mohd Sohadi et al. Control of blood glucose level for type 1 diabetes mellitus using improved Hovorka equations: comparison between clinical and in-silico works
Prud'Homme et al. Preclinically assessed optimal control of postprandial glucose excursions for type 1 patients with diabetes
HK1182496B (en) Insulin delivery device
Basha et al. Evolution of Diabetic Control Identification in Lieu of Continuous Glucose Monitoring Technology-A

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141006

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20141006

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20151104

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151120

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160426

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160720

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160726

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20161213

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20161215

R150 Certificate of patent or registration of utility model

Ref document number: 6062859

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250